{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:13:00Z","timestamp":1785831180719,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.schres.2012.10.015","type":"journal-article","created":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T20:01:49Z","timestamp":1352923309000},"page":"215-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Interventions to reduce antipsychotic polypharmacy: A systematic review"],"prefix":"10.1016","volume":"143","author":[{"given":"Hideaki","family":"Tani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2012.10.015_bb0005","series-title":"Practice Guideline for the Treatment of Patients with Schizophrenia","author":"American Psychiatric Association","year":"2004"},{"key":"10.1016\/j.schres.2012.10.015_bb0010","series-title":"Texas Medication Algorithm Project Procedural Manual: Schizophrenia Algorithm","author":"Argo","year":"2008"},{"issue":"5","key":"10.1016\/j.schres.2012.10.015_bb0015","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1600-0447.2010.01553.x","article-title":"Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients","volume":"122","author":"Baandrup","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.schres.2012.10.015_bb0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1742-1241.2010.02544.x","article-title":"Patient adherence to medication requirements for therapy of type 2 diabetes","volume":"65","author":"Bailey","year":"2011","journal-title":"Int. J. Clin. Pract."},{"issue":"9","key":"10.1016\/j.schres.2012.10.015_bb0025","first-page":"690","article-title":"A study of the effect of computer feedback on polypharmacy","volume":"39","author":"Barton","year":"1978","journal-title":"J. Clin. Psychiatry"},{"issue":"16","key":"10.1016\/j.schres.2012.10.015_bb0030","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2146\/ajhp080238","article-title":"Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy","volume":"66","author":"Benner","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"1","key":"10.1016\/j.schres.2012.10.015_bb0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"issue":"13 Suppl. 1","key":"10.1016\/j.schres.2012.10.015_bb0040","first-page":"7S","article-title":"Clinical practice guidelines. Treatment of schizophrenia","volume":"50","author":"Canadian Psychiatric Association","year":"2005","journal-title":"Can. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2012.10.015_bb0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.47102\/annals-acadmedsg.V35N7p457","article-title":"Reducing polypharmacy through the introduction of a treatment algorithm: use of a treatment algorithm on the impact on polypharmacy","volume":"35","author":"Chong","year":"2006","journal-title":"Ann. Acad. Med. Singapore"},{"issue":"3","key":"10.1016\/j.schres.2012.10.015_bb0050","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006324.pub2","article-title":"Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia","author":"Cipriani","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.schres.2012.10.015_bb0055","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10597-009-9288-2","article-title":"Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program","volume":"46","author":"Constantine","year":"2010","journal-title":"Community Ment. Health J."},{"issue":"2","key":"10.1016\/j.schres.2012.10.015_bb0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"1\u20133","key":"10.1016\/j.schres.2012.10.015_bb0065","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.schres.2011.02.016","article-title":"Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior","volume":"131","author":"Correll","year":"2011","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.schres.2012.10.015_bb0070","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","article-title":"Effectiveness of switching from antipsychotic polypharmacy to monotherapy","volume":"168","author":"Essock","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2012.10.015_bb0075","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15622970500483177","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia","volume":"7","author":"Falkai","year":"2006","journal-title":"World J. Biol. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2012.10.015_bb0080","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1176\/ps.62.10.pss6210_1124","article-title":"Long-term impact of web-based tools, leadership feedback, and policies on inpatient antipsychotic polypharmacy","volume":"62","author":"Finnerty","year":"2011","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2012.10.015_bb0085","first-page":"1","article-title":"Critical review of antipsychotic polypharmacy in the treatment of schizophrenia","author":"Fleischhacker","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.schres.2012.10.015_bb0090","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1176\/ps.2007.58.7.1007","article-title":"Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999\u20132004","volume":"58","author":"Gilmer","year":"2007","journal-title":"Psychiatr. Serv."},{"issue":"11","key":"10.1016\/j.schres.2012.10.015_bb0095","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/00005053-198911000-00005","article-title":"Multiple versus single antipsychotic drug treatment in chronic psychosis","volume":"177","author":"Godleski","year":"1989","journal-title":"J. Nerv. Ment. Dis."},{"issue":"6","key":"10.1016\/j.schres.2012.10.015_bb0100","first-page":"393","article-title":"Development and delivery of a quality improvement program to reduce antipsychotic polytherapy","volume":"16","author":"Goren","year":"2010","journal-title":"J. Manag. Care Pharm."},{"issue":"7","key":"10.1016\/j.schres.2012.10.015_bb0105","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1440-1819.2011.02280.x","article-title":"Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia","volume":"65","author":"Hazra","year":"2011","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2012.10.015_bb0110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1192\/bjp.187.3.243","article-title":"Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription","volume":"187","author":"Ito","year":"2005","journal-title":"Br. J. Psychiatry"},{"issue":"Suppl. 12","key":"10.1016\/j.schres.2012.10.015_bb0115","first-page":"1","article-title":"The Expert Consensus Guideline Series. Optimizing pharmacologic treatment of psychotic disorders","volume":"64","author":"Kane","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2012.10.015_bb0120","first-page":"287","article-title":"Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder","volume":"11","author":"Koen","year":"2008","journal-title":"Afr. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2012.10.015_bb0125","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/archpsyc.1980.01780200102013","article-title":"Automated review system for orders of psychotropic drugs","volume":"37","author":"Laska","year":"1980","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2012.10.015_bb0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-244X-11-118","article-title":"Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study","volume":"11","author":"Misawa","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2012.10.015_bb0135","series-title":"The NICE Guidelines on core interventions in the treatment and management of schizophrenia in primary and secondary care (update)","author":"National Collaborating Centre for Mental Health","year":"2010"},{"issue":"5","key":"10.1016\/j.schres.2012.10.015_bb0140","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1600-0447.2010.01576.x","article-title":"10-year trends in the treatment and outcomes of patients with first-episode schizophrenia","volume":"122","author":"Nielsen","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"issue":"7","key":"10.1016\/j.schres.2012.10.015_bb0145","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/MLR.0b013e3181653d43","article-title":"The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia","volume":"46","author":"Owen","year":"2008","journal-title":"Med. Care"},{"issue":"2","key":"10.1016\/j.schres.2012.10.015_bb0150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/0269881103017002012","article-title":"Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients","volume":"17","author":"Paton","year":"2003","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2012.10.015_bb0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1176\/appi.ps.57.1.21","article-title":"Best practices: AN initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital","volume":"57","author":"Patrick","year":"2006","journal-title":"Psychiatr. Serv."},{"issue":"5","key":"10.1016\/j.schres.2012.10.015_bb0160","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4088\/JCP.08m04912gre","article-title":"Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients","volume":"71","author":"Procyshyn","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2012.10.015_bb0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.schres.2012.10.015_bb0170","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/11539830-000000000-00000","article-title":"Changes in antipsychotic medication use after implementation of a Medicaid mental health carve-out in the US","volume":"30","author":"Robst","year":"2012","journal-title":"PharmacoEconomics"},{"issue":"1\u20132","key":"10.1016\/j.schres.2012.10.015_bb0175","first-page":"1","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders","volume":"39","author":"Royal Australian and New Zealand College of Psychiatrists","year":"2005","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2012.10.015_bb0180","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/pds.2083","article-title":"Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy","volume":"20","author":"Santone","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"10.1016\/j.schres.2012.10.015_bb0185","first-page":"186","article-title":"Antipsychotic drugs: can education change prescribing practices?","volume":"40","author":"Schroeder","year":"1979","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2012.10.015_bb0190","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1176\/appi.ps.57.1.127","article-title":"High-cost use of second-generation antipsychotics under California's Medicaid program","volume":"57","author":"Stahl","year":"2006","journal-title":"Psychiatr. Serv."},{"issue":"2","key":"10.1016\/j.schres.2012.10.015_bb0195","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1017\/S1461145703004012","article-title":"Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia","volume":"7","author":"Suzuki","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2012.10.015_bb0200","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1176\/appi.ps.54.1.55","article-title":"Combination antipsychotic therapy in clinical practice","volume":"54","author":"Tapp","year":"2003","journal-title":"Psychiatr. Serv."},{"issue":"5","key":"10.1016\/j.schres.2012.10.015_bb0205","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1017\/S003329170700147X","article-title":"The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards - a cluster randomized controlled trial","volume":"38","author":"Thompson","year":"2008","journal-title":"Psychol. Med."},{"issue":"1\u20133","key":"10.1016\/j.schres.2012.10.015_bb0210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.schres.2011.05.013","article-title":"The evolution of antipsychotic switch and polypharmacy in natural practice\u2014a longitudinal perspective","volume":"130","author":"Tsutsumi","year":"2011","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.schres.2012.10.015_bb0215","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/JCP.0b013e3181bf4ea3","article-title":"D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia","volume":"29","author":"Uchida","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2012.10.015_bb0220","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1440-1819.1997.tb03204.x","article-title":"Modifying psychotropic drug prescription patterns: a follow-up survey","volume":"51","author":"Ungvari","year":"1997","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2012.10.015_bb0225","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2007-970062","article-title":"Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia","volume":"40","author":"Xiang","year":"2007","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.schres.2012.10.015_bb0230","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0031-1286345","article-title":"Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009)","volume":"45","author":"Xiang","year":"2012","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1016\/j.schres.2012.10.015_bb0235","first-page":"690","article-title":"The trend for megadose polypharmacy in antipsychotic pharmacotherapy: a prescription survey conducted by the psychiatric clinical pharmacy research group","volume":"114","author":"Yoshio","year":"2012","journal-title":"Jpn. J. Psychiatry Neurol."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412005877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412005877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:24:01Z","timestamp":1760297041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996412005877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0920996412005877"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2012.10.015","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interventions to reduce antipsychotic polypharmacy: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2012.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}